The company’s bupivacaine will be available in six single-dose and two multi-dose latex-free vials. According to IMS data, the 2011 U.S. market for injectable bupivacaine approximates $29 million.
Bupivacaine is the 13th product approved under the joint venture between Sagent and Strides Arcolab. Under the collaboration, Strides is responsible for developing and supplying injectable products that Sagent will market in the U.S.
Related Articles on Anesthesia:
Gabapentin Does Not Decrease Pain After Total Knee Arthroplasty
Popliteal Blocks Cause Rebound Pain After Ankle Fracture Surgery
Type of General Anesthesia Does Not Increase Delirium in Post-Op Period
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
